Neos Therapeutics develops, manufactures, and commercializes branded products using our proprietary, extended-release drug delivery technology platform. We have used this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. We are also using this technology to develop two additional product candidates:
- Oral disintegrating tablets (ODT)
- Oral suspension dosage forms.
In 2014 alone, 63.1 million prescriptions for medications with ADHD labeling, principally in extended-release formulations, were written in the United States. The vast majority of currently available dosage forms for ADHD are tablets and capsules. Our technology provides a plasma concentration-time profile that is consistent with once-daily dosing in an orally disintegrating tablet that allows the tablet to disintegrate in the mouth without water.